Utilisation of novel anti-platelet agents: Evidence, guidelines and proven patients' value

Thrombosis and Haemostasis

Volumn 112, Issue 1, 2014, Pages 12-14

  Wallentin, Lars ^a,b   Himmelmann, Anders ^c   Storey, Robert F ^d   Steg, Philippe Gabriel ^e,f,g,h   Harrington, Robert A ⁱ  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e INSERM   (France)

^f BICHAT HOSPITAL   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁱ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICAGRELOR; ADENOSINE; PIPERAZINE DERIVATIVE; PRASUGREL; THIOPHENE DERIVATIVE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; DRUG UTILIZATION; EVIDENCE BASED PRACTICE; HEART INFARCTION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); COST; ECONOMICS; EVIDENCE BASED MEDICINE; HUMAN; INTERNATIONAL COOPERATION; MARKETING; PATIENT SATISFACTION;

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONAL COOPERATION; MARKETING; PATIENT SATISFACTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; THIOPHENES; TICLOPIDINE;

EID: 84903757187     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-04-0328     Document Type: Article

References (12)

1. Serebruany V, Fortmann SD. Underutilization of novel antiplatelet agents: myths, generics, and challenged shareholder's value. Thromb Haemost 2014; 112: 4-9.
2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
3. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the european society of cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
4. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-425.
5. Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e179-347.
6. Storey RF, James SK, Siegbahn A, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the plato study. Platelets 2013; Epub ahead of print.
7. Varenhorst C, Alstrom U, Scirica BM, et al. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 2012; 60: 1623-1630.
8. Mahaffey KW, Held C, Wojdyla DM, et al. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2014; 63: 1493-1499.
9. Held C, Asenblad N, Bassand JP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO (Patelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57: 672-684.
10. Nikolic E, Janzon M, Hauch O, et al. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: Results from the PLATO study. Eur Heart J 2013; 34: 220-228.
11. Ticagrelor for acute coronary syndrome? Drug Ther Bull 2011; 49: 66-68.
12. Gandjour A, Gafni A, Schlander M. Determining the price for pharmaceuticals in Germany: Comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor. Expert Rev Pharmacoecon Outcomes Res 2014; 14: 123-129.